Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colonic Neoplasms 4Pancreatic Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Colorectal Neoplasms 2Clinical Stage I Gastric Cancer AJCC v8 2Anus Neoplasms 2Tongue Neoplasms 1Sinonasal undifferentiated carcinoma 1Salivary Gland Neoplasms 1Paranasal Sinus Neoplasms 1Pancreatic Adenocarcinoma 1PRETEXT I Hepatoblastoma 1Oropharyngeal Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Klatskin Tumor 1Keratosis, Actinic 1Hypopharyngeal Neoplasms 1Hepatoblastoma 1HIV Infections 1Gallbladder Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Epstein-Barr Virus Infections 1DNA Repair-Deficiency Disorders 1Colorectal Neoplasms, Hereditary Nonpolyposis 1

Interventions

pembrolizumab 25Cyclophosphamide 20Nivolumab 13Doxorubicin 13Carboplatin 10Surveys and Questionnaires 9Paclitaxel 9Exercise 9atezolizumab 8Vincristine 8Rituximab 8Radiotherapy 8Prednisone 8Dexamethasone 8Bevacizumab 8venetoclax 7fludarabine 7Pemetrexed 7Fluorouracil 7Docetaxel 7Blood Specimen Collection 7lenvatinib 6dostarlimab 6cemiplimab 6budigalimab 6Oxaliplatin 6Cisplatin 6durvalumab 5Leucovorin 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms × dehydroftorafur × Clear all
NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
38 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡